Jun 21, 2016 9:15am EDT SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants
Jun 20, 2016 8:00am EDT SCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections
Jun 10, 2016 9:05am EDT SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016
Jun 08, 2016 4:05pm EDT SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors
May 13, 2016 8:00am EDT SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections
May 09, 2016 9:25am EDT SCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update
Apr 19, 2016 9:15am EDT SCYNEXIS Receives Designation as a Small and Medium Enterprise by the European Medicines Agency
Apr 15, 2016 9:00am EDT SCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis
